Arsenic significantly enhanced the expression of LC3 in NSCLC tumor cells (p < 0.001, p < 0.01, Figure 5B,F), but gefitinib had a weak effect on the expression of LC3 and P62 in tumor cells from patients harboring various EGFR genotypes (Figure 5A–F). Here, MAP1LC3A is linked to neoplasm.